# Molina Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2026

- Company: [Molina Healthcare, Inc.](/companies/moh.md) (CIK 1179929)
- Form: 10-Q
- Filed: 2026-10-22
- Accepted by EDGAR: Oct 22, 2026, 09:23 ET
- Period: 2026-09-30
- Accession: 0001179929-26-000045
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1179929/000117992926000045/moh-20260930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1179929/000117992926000045/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-07-01 to 2026-09-30 | $11.08bn | us-gaap:Revenues |
| Revenue | 9 months, 2026-01-01 to 2026-09-30 | $32.75bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2026-07-01 to 2026-09-30 | $9.72bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2026-01-01 to 2026-09-30 | $28.43bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months, 2026-07-01 to 2026-09-30 | $106.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2026-01-01 to 2026-09-30 | $334.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2026-07-01 to 2026-09-30 | $53.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2026-01-01 to 2026-09-30 | $161.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2026-07-01 to 2026-09-30 | $15.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2026-01-01 to 2026-09-30 | $61.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-07-01 to 2026-09-30 | $38.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2026-01-01 to 2026-09-30 | $112.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-07-01 to 2026-09-30 | $0.73 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2026-01-01 to 2026-09-30 | $2.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-07-01 to 2026-09-30 | $0.74 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2026-01-01 to 2026-09-30 | $2.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-07-01 to 2026-09-30 | 51,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2026-01-01 to 2026-09-30 | 51,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2026-01-01 to 2026-09-30 | $629.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2026-01-01 to 2026-09-30 | $94.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2026-01-01 to 2026-09-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2026-09-30 | $4.48bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2026-09-30 | $12.51bn | us-gaap:AssetsCurrent |
| Total assets | at 2026-09-30 | $15.65bn | us-gaap:Assets |
| Current liabilities | at 2026-09-30 | $7.39bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-09-30 | $11.50bn | us-gaap:Liabilities |
| Long-term debt | at 2026-09-30 | $3.77bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2026-09-30 | $4.16bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1179929/000117992926000045/moh-20260930.htm

Filed Oct 22, 2026.
Source: SEC EDGAR, the filing index for accession 0001179929-26-000045. Last ingested by Listed: Nov 15, 2026, 00:39 ET. No prices; not investment advice.
